
Antibodies | Selected Papers on Cancer Immunotherapy
We are pleased to highlight 15 notable papers on cancer immunotherapy published in Antibodies (ISSN: 2073-4468) in 2024 and 2025. We invite you to explore these contributions, which reflect recent advances and emerging directions in cancer immunotherapy.
1. “Immune Cell Engagers: Advancing Precision Immunotherapy for Cancer Treatment”
by Hyukmin In, Minkyoung Park, Hyeonsik Lee and Kyung Ho Han
Antibodies 2025, 14(1), 16; https://doi.org/10.3390/antib14010016
Available online: https://www.mdpi.com/2073-4468/14/1/16
2. “TLR2 and TLR9 Blockade Using Specific Intrabodies Inhibits Inflammation-Mediated Pancreatic Cancer Cell Growth”
by Amrendra K. Ajay, Martin Gasser, Li-Li Hsiao, Thomas Böldicke and Ana Maria Waaga-Gasser
Antibodies 2024, 13(1), 11; https://doi.org/10.3390/antib13010011
Available online: https://www.mdpi.com/2073-4468/13/1/11
3. “Anti-MET Antibody Therapies in Non-Small-Cell Lung Cancer: Current Progress and Future Directions”
by Kinsley Wang and Robert Hsu
Antibodies 2024, 13(4), 88; https://doi.org/10.3390/antib13040088
Available online: https://www.mdpi.com/2073-4468/13/4/88
4. “Anastrozole and Tamoxifen Impact on IgG Glycome Composition Dynamics in Luminal A and Luminal B Breast Cancers”
by Borna Rapčan, Matko Fančović, Tea Pribić, Iva Kirac, Mihaela Gaće, Frano Vučković and Gordan Lauc
Antibodies 2024, 13(1), 9; https://doi.org/10.3390/antib13010009
Available online: https://www.mdpi.com/2073-4468/13/1/9
5. “Balancing the Affinity and Tumor Cell Binding of a Two-in-One Antibody Simultaneously Targeting EGFR and PD-L1”
by Julia Harwardt, Felix Klaus Geyer, Katrin Schoenfeld, David Baumstark, Vera Molkenthin and Harald Kolmar
Antibodies 2024, 13(2), 36; https://doi.org/10.3390/antib13020036
Available online: https://www.mdpi.com/2073-4468/13/2/36
6. “Targeting Neoantigens in Cancer: Possibilities and Opportunities in Breast Cancer”
by Zuhair Chaudhry, Anik Boyadzhyan, Kayvan Sasaninia and Vikrant Rai
Antibodies 2024, 13(2), 46; https://doi.org/10.3390/antib13020046
Available online: https://www.mdpi.com/2073-4468/13/2/46
7. “Targeting CD44 and EpCAM with Antibody Dye Conjugates for the Photoimmunotherapy of Prostate Cancer”
by Isis Wolf, Susanne Schultze-Seemann, Christian Gratzke and Philipp Wolf
Antibodies 2025, 14(1), 5; https://doi.org/10.3390/antib14010005
Available online: https://www.mdpi.com/2073-4468/14/1/5
8. “Development of Fully Human Antibodies Targeting SIRPα and PLA2G7 for Cancer Therapy”
by Seungmin Shin, Du-San Baek, John W. Mellors, Dimiter S. Dimitrov and Wei Li
Antibodies 2025, 14(1), 21; https://doi.org/10.3390/antib14010021
Available online: https://www.mdpi.com/2073-4468/14/1/21
9. “Identification of a Fully Human Antibody VH Domain Targeting Anaplastic Lymphoma Kinase (ALK) with Applications in ALK-Positive Solid Tumor Immunotherapy”
by Chuan Chen, Zehua Sun, Zening Wang, Seungmin Shin, Abigail Berrios, John W. Mellors, Dimiter S. Dimitrov and Wei Li
Antibodies 2024, 13(2), 39; https://doi.org/10.3390/antib13020039
Available online: https://www.mdpi.com/2073-4468/13/2/39
10. “177Lu Anti-Angiogenic Radioimmunotherapy Targeting ATP Synthase in Gastric Cancer Model”
by Bok-Nam Park, Young-Sil An, Su-Min Kim, Su-Jin Lee, Yong-Jin Park and Joon-Kee Yoon
Antibodies 2024, 13(3), 51; https://doi.org/10.3390/antib13030051
Available online: https://www.mdpi.com/2073-4468/13/3/51
11. “Preventative Cancer Vaccine-Elicited Human Anti-MUC1 Antibodies Have Multiple Effector Functions”
by Michelle L. McKeague, Jason Lohmueller, Matthew T. Dracz, Najla Saadallah, Eric D. Ricci, Donella M. Beckwith, Ramya Ayyalasomayajula, Maré Cudic and Olivera J. Finn
Antibodies 2024, 13(4), 85; https://doi.org/10.3390/antib13040085
Available online: https://www.mdpi.com/2073-4468/13/4/85
12. “Fragment-Based Immune Cell Engager Antibodies in Treatment of Cancer, Infectious and Autoimmune Diseases: Lessons and Insights from Clinical and Translational Studies”
by Ge Yang and Mohammad Massumi
Antibodies 2025, 14(3), 52; https://doi.org/10.3390/antib14030052
Available online: https://www.mdpi.com/2073-4468/14/3/52
13. “A Novel Tetravalent Bispecific Immune Cell Engager Activates Natural Killer Cells to Kill Cancer Cells without Mediating Fratricide”
by Ge Yang, Shahryar Khoshtinat Nikkhoi, Hajar Owji, Geng Li, Mohammad Massumi, Jessica Cervelli, Venu Gopal Vandavasi and Arash Hatefi
Antibodies 2024, 13(3), 75; https://doi.org/10.3390/antib13030075
Available online: https://www.mdpi.com/2073-4468/13/3/75
14. “Comparative Evaluation of Three Primary Antibody Clones for p16 Immunohistochemistry in Gynecologic Tumors”
by Hiroshi Yoshida, Ayumi Sugitani, Mayumi Kobayashi-Kato, Masaya Uno and Mitsuya Ishikawa
Antibodies 2025, 14(3), 77; https://doi.org/10.3390/antib14030077
Available online: https://www.mdpi.com/2073-4468/14/3/77
by Tristan Mangeat, Célestine Mairaville, Myriam Chentouf, Madeline Neiveyans, Martine Pugnière, Giang Ngo, Vincent Denis, Corentin Catherine, Alexandre Pichard, Emmanuel Deshayes et al.
Antibodies 2025, 14(4), 83; https://doi.org/10.3390/antib14040083
Available online: https://www.mdpi.com/2073-4468/14/4/83